Rapidly deteriorating growth forecast for global Pharma, as patents expire; in Germany, price cuts will take a toll
Growth will slow to just 1.3% to 2015 for the branded prescription pharmaceutical industry’s leading companies, according to latest research from independent market analyst, Datamonitor.
Between 2003 and 2009, theses same companies enjoyed robust sales growth at a compound annual growth rate (CAGR) of 7.1%. Sharp declines in branded sales following the loss of patent exclusivity will drive this rapid deterioration in growth.
Simon King, pharmaceutical company analyst at Datamonitor, comments: “The difficulty in developing new products, particularly those that can generate sufficient sales to compensate for blockbuster expiries, has compounded this problem. This has driven a steady shift away from blockbuster-centric growth strategies towards diversification into other areas of the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze